title: A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis.
abstract: Pharmacotherapeutic options for multiple sclerosis (MS)-related fatigue are limited. Thirty patients were randomly assigned to aspirin (ASA) 1,300 mg/day or placebo in a double-blind crossover study. Results favored ASA for the main clinical outcomes: Modified Fatigue Impact Scale scores (p = 0.043) and treatment preference (p = 0.012). There were no significant adverse effects. The results warrant further study and support a role for ASA-influenced mechanisms, perhaps immunologic, in the generation of MS-related chronic fatigue.
authors.affiliation: Department of Neurology Mayo Clinic, Scottsdale, AZ 85259, USA. wingerchuk.dean@mayo.edu
authors.forename: D M
authors.initials: DM
authors.lastname: Wingerchuk
authors.forename: E E
authors.initials: EE
authors.lastname: Benarroch
authors.forename: P C
authors.initials: PC
authors.lastname: O'Brien
authors.forename: B M
authors.initials: BM
authors.lastname: Keegan
authors.forename: C F
authors.initials: CF
authors.lastname: Lucchinetti
authors.forename: J H
authors.initials: JH
authors.lastname: Noseworthy
authors.forename: B G
authors.initials: BG
authors.lastname: Weinshenker
authors.forename: M
authors.initials: M
authors.lastname: Rodriguez
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000367:Age Factors; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D018592:Cross-Over Studies; D018450:Disease Progression; D004311:Double-Blind Method; D005221:Fatigue / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications*; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin